1. Nov. 25, 2012

2. Corindus Inc.
Graduated from: TEIC Incubator Company Stage: R&D Established: 2002
Corindus is a global technology leader in robotic-assisted percutaneous coronary
interventions. The company’s CorPath[R] 200 System offers interventional cardiologists
complete PCI procedure control from an interventional cockpit. The CorPath open-platform
technology and intellectual property will enable Corindus to address other segments of the
vascular market, including peripheral, neuro and structural heart applications.
Technology
Vascular Robotics.
The proprietary technology utilizes physician fluoroscopic control similar to routine practice to
allow maneuvering and torquing of cath lab devices. Initial clinical trials have demonstrated
CorPath’s safety and efficacy. Unique to CorPath(TM) is the simplicity of integration into
existing cath lab systems.
Product Phase
CorPath Clinical Trials
2012 - FDA clearance for the CorPath System
Researcher: Prof. Rafael Beyar
www.corindus.com

3. Regentis Biomaterials
Regentis Biomaterials is a tissue repair company that is developing and commercializing
innovative biodegradable hydrogels for the local repair of damaged cartilage and bone. The
platform technology is a family of hydrogels called Gelrin™. These gels can be injected or
applied to a specific local site and offer beneficial properties for the local repair of damaged
tissue such as cartilage and bone.
The Gelrin™ technology offers off-the-shelf products that are
designed to be suitable for both open surgery and minimally
invasive procedures. An ideal solution for physicians and their
patients, the products are easy to implant and have been shown
to stimulate the regeneration of healthy cartilage and bone
tissue.
http://www.regentis.co.il

4. Invision Biometrics
From: Calcalist, Oct. 30, 2011:
“Intel negotiates $50M acquisition of Invision Biometrics
Chip giant Intel aims to take Israel's Invision onboard in bid to take on Microsoft's; Invision
investors expected to gain 20 times their original input
Invision Biometrics, is a developer of 3D sensor PCBs which detect face and body movement
and translate them into on-screen game moves.“
http://www.ynetnews.com/articles/0,7340,L-4141247,00.html
Researcher: Prof. Ron Kimmel

5. Azilect/Agilect (Rasagiline)
An anti-Parkinson's disease drug
Developed by Teva Pharmaceuticals in cooperation with Prof. Moussa Youdim and
Prof. John Finberg
Parkinson’s disease is a progressive condition that involves a gradual loss of nerve
cell function in the brain. The nerve cells that are specifically affected are those
that control body movement
~ 4 million people worldwide suffer from Parkinson's disease; it affects
approximately 2-4% of the population over the age of 60, 1-2% in the general
population
Agilect®/Azilect®- Azilect® was launched in Israel in March 2005

6. Technology Transfer Issues
 How is it done at the Technion?
 Can we do it better?
 How lucrative is technology Transfer?
 Why do technology transfer?

7. Intellectual Property
Spin off
Licensing
Dilution Companies
1st round investment
2nd round investment
3rd round investment

8. Internal Sources for Advancement of IP
 Previously, about $600K per year
 Then, a “dry period”
 Currently, new funding is available
 The Kamin Program

9. AMIT
Alfred Mann Institute for Biomedical Development at the Technion
Currently runs 4 projects:
 A biomimetic surgical tissue adhesive, entered
Clinical Trials in October
 A innovative device for Glaucoma surgeries
 Stem Cells; suspension culture enabling platform for
large scale expansion of human pluripotent stem
cells
An experimental drug:
 An anti-cancer compound, targeting cancer cells by
a unique mechanism
~$25M over 2007-2012
$4.25 committed for 2013

10. AMIT Spinoff: Sealantis
Biomimetic adhesives for medical applications:
The remarkable ability of algae to attach to wet solid
Surface  finding a material that will have similar
capabilities yet its commercial roduction will not rely on
extracting natural materials.
Compounds were mainly selected due to their
chemical similarity to the components of the natural
algae glue.